Diabetes Study of Linagliptin and Empagliflozin in Children and Adolescents (DINAMO)TM
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 175 participants.
Also called NCT03429543
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 175 participants
- Sponsor
- Registry
-
NCT03429543 -
2016-000669-21
-
- Other papers using this trial's data
- Efficacy and safety of the SGLT2 inhibitor empagliflozin versus placebo and the DPP-4 inhibitor linagliptin versus placebo in young people with type 2 diabetes (DINAMO): a multicentre, randomised, double-blind, parallel group, phase 3 trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Argentina, Brazil, Canada, China, Colombia, Germany, Israel, Mexico, Puerto Rico, Russia, South Korea, Thailand, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT03429543. Randomized; double masking; primary purpose treatment. Start 2018-03-20 (actual); primary completion 2022-10-19 (actual). Results posted on 2024-02-23.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Diabetes Study of Linagliptin and Empagliflozin in Children and Adolescents (DINAMO)TM
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- Metformin
- Intervention (Drug)
- Insulin
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- Linagliptin
- Intervention (Drug)
- Empagliflozin
- Lead sponsor
- Boehringer Ingelheim
Record details
- Record id
cardio:ct-nct03429543- Content hash
a610cbbaf48e90525c0ab70207d5acf9509817a0fdf7cafdd2ea24dac0a25ea8